[Show abstract] [Hide abstract]
ABSTRACT: Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted.Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3%) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5%) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4%) experienced a recurrence of AF. Multivariate Cox proportional-hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95% confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95% CI 0.299-1.466).This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.
International Heart Journal 01/2011; 52(2):103-6. DOI:10.1536/ihj.52.103 · 1.07 Impact Factor